HRs for myocardial infarction associated with factors controlled in the multivariate Cox models*
HR | 95% CI | |
---|---|---|
Male | 1.39 | 0.98 to 1.99 |
Socioeconomic status (SES) | 0.97 | 0.95 to 0.99 |
Seropositive (referent to seronegative) | 1.23 | 1.03 to 1.48 |
Missing serology (referent to seronegative) | 1.30 | 1.05 to 1.59 |
Current smoker (referent to never smoker) | 1.42 | 1.14 to 1.77 |
Former smoker (referent to never smoker) | 1.08 | 0.89 to 1.31 |
Missing smoking data (referent to never smoker) | 1.72 | 1.26 to 2.34 |
Steroids 1–7.5 mg/day (ref to no use)† | 1.32 | 1.13 to 1.54 |
Steroids >7.5 mg/day (ref to no use)† | 1.75 | 1.42 to 2.15 |
Statin | 1.43 | 1.24 to 1.65 |
Methotrexate (MTX)+DMARD (ref to non-biological DMARD other than MTX) | 0.83 | 0.65 to 1.00 |
Biologics‡ (ref to non-biological DMARD other than MTX) | 0.82 | 0.65 to 1.05 |
No RA medication (no biological, no DMARD; ref to non-biological DMARD other than MTX) | 0.87 | 0.72 to 1.06 |
Chronic obstructive pulmonary disease | 1.54 | 1.27 to 1.86 |
Chronic kidney disease | 2.30 | 1.60 to 3.32 |
Diabetes mellitus | 1.76 | 1.48 to 2.09 |
Heart failure | 1.71 | 1.28 to 2.28 |
Hypertension | 1.06 | 0.92 to 1.23 |
Note: These are the covariates controlled for in the adjusted Cox models (HRs) models depicted in figure 2.
*Models also controlled for body mass index, but not statistically significant. Comorbidities determined and controlled for at baseline.
†Steroid dose calculated as the mean daily dose during the 6 months prior to the index date.
‡Biological included all antitumor necrosis factor biologics, rituximab and abatacept with or without non-biological DMARD.
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.